COGT earnings analysis
What we found in COGT's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The extracted 10-Q section contains no income statement, balance sheet, cash flow, segment, or quantitative guidance data, so period-over-period operating trends cannot be assessed. Disclosure controls were deemed effective as of June 30, 2026, and no material changes to internal controls were reported. The filing states that risk factors and market risks were unchanged from the 2025 Form 10-K, while disclosing new director and executive Rule 10b5-1 trading plans.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Disclosure controls effective
- Management concluded that disclosure controls and procedures were effective at the reasonable assurance level as of June 30, 2026.
- Internal controls unchanged
- No change during the three months ended June 30, 2026 materially affected, or was reasonably likely to materially affect, internal control over financial reporting.
- Director trading plan disclosed
- Director Arlene Morris adopted a Rule 10b5-1 plan on May 28, 2026 to sell up to 45,510 shares through July 31, 2027, subject to pricing and other conditions.
- Second director trading plan
- Director Karen Ferrante adopted a Rule 10b5-1 plan on June 25, 2026 to sell up to 63,399 shares through June 25, 2027, subject to pricing and other conditions.
- CEO equity plan disclosed
- CEO Andrew Robbins' July 30, 2026 plan covers sales of up to 201,061 shares and exercise of 57,661 incentive stock options, with the plan expiring no later than June 30, 2027.
- CFO equity plan disclosed
- CFO John Green's July 30, 2026 plan covers sales of up to 157,337 shares and exercise of 62,619 incentive stock options, with the plan expiring no later than June 30, 2027.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- No updated risk-factor disclosure
- The company stated there were no material changes to the risk factors in its 2025 Form 10-K filed February 17, 2026; therefore, this filing does not identify a newly elevated risk factor.
- Multiple executive selling plans
- Executive Rule 10b5-1 plans disclosed on July 30, 2026 permit sales of up to 201,061 shares by the CEO, 157,337 shares by the CFO, 27,000 shares by the CMO and 116,700 shares by the CLO, subject to pricing and other conditions.
- Litigation and market-risk exposure
- The company stated there were no material changes to market risks described in its 2025 Form 10-K filed February 17, 2026; however, the filing also notes that litigation and claims could adversely affect the company through defense and settlement costs and management-resource diversion.
What they said about what is next.
The extracted 10-Q text provides no quantitative revenue or EPS outlook. No change in outlook can be assessed from this filing.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 5, 2026
- Cogent Biosciences experienced a significant increase in net losses in Q1 2026, amounting to $97.4 million compared to $71.99 million in Q1 2025. The company's cash position remains strong at $866.4 million, projected…
- 10-K · February 17, 2026
- Cogent is a clinical‑stage biotech focused on bezuclastinib (KIT D816V / exon 17) with positive 2025 registrational readouts across NonAdvSM, AdvSM and GIST and NDAs submitted/being submitted; the company expects a U.S.…
- 10-Q · May 6, 2025
- Cogent reported a quarterly net loss of $71,986 (three months ended March 31, 2025) vs $58,348 in the year-ago quarter, driven by higher R&D and G&A spend. Cash and short-term investments total $245,661 ($126,003 cash…
- 10-K · February 25, 2025
- Cogent’s 10-K emphasizes clinical progress for lead asset bezuclastinib with completed enrollment in registration-directed trials (SUMMIT Part 2 enrolled 179 patients in Q4 2024; APEX Part 2 completed enrollment with 58…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing COGT makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever